Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis.
Publication/Presentation Date
11-1-2021
Abstract
Patients with refractory chronic migraine have substantial disability and have failed many acute and preventive medications. When aggressive intravenous therapy is indicated, both lidocaine and (R,S)-ketamine infusions have been used successfully to provide relief. Retrospective studies have shown that both agents may be associated with short-term analgesia. In this prospective, observational pilot study of 6 patients, we compared the effects of lidocaine and (R,S)-ketamine infusions and performed metabolite analyses of (R,S)-ketamine to determine its metabolic profile in this population. One of (R,S)-ketamine's metabolites, (2R,6R)-hydroxynorketamine, has been shown in animal studies to reduce pain, but human studies in patients undergoing continuous (R,S)-ketamine infusions for migraine are lacking. All 6 patients tolerated both infusions well with mild adverse effects. The baseline mean pain rating (0-10 numeric rating scale) decreased from 7.5 ± 2.2 to 4.7 ± 2.8 by end of lidocaine treatment (
Volume
61
Issue
11
First Page
1421
Last Page
1429
ISSN
1552-4604
Published In/Presented At
Schwenk, E. S., Torjman, M. C., Moaddel, R., Lovett, J., Katz, D., Denk, W., Lauritsen, C., Silberstein, S. D., & Wainer, I. W. (2021). Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. Journal of clinical pharmacology, 61(11), 1421–1429. https://doi.org/10.1002/jcph.1920
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34125442
Department(s)
Administration and Leadership
Document Type
Article